<!-- Generated by pkgdown: do not edit by hand -->
<!DOCTYPE html>
<html lang="en">
  <head>
  <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Treatment cost parameters — params_costs_tx • iviNSCLC</title>

<!-- jquery -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js" integrity="sha256-FgpCb/KJQlLNfOu91ta32o/NMZxltwRo8QtmkMRdAu8=" crossorigin="anonymous"></script>
<!-- Bootstrap -->
<link href="https://cdnjs.cloudflare.com/ajax/libs/bootswatch/3.3.7/simplex/bootstrap.min.css" rel="stylesheet" crossorigin="anonymous" />

<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha256-U5ZEeKfGNOja007MMD3YBI0A3OSZOQbeG6z2f2Y0hu8=" crossorigin="anonymous"></script>

<!-- Font Awesome icons -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous" />

<!-- clipboard.js -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.4/clipboard.min.js" integrity="sha256-FiZwavyI2V6+EXO1U+xzLG3IKldpiTFf3153ea9zikQ=" crossorigin="anonymous"></script>

<!-- sticky kit -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/sticky-kit/1.1.3/sticky-kit.min.js" integrity="sha256-c4Rlo1ZozqTPE2RLuvbusY3+SU1pQaJC0TjuhygMipw=" crossorigin="anonymous"></script>

<!-- pkgdown -->
<link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script>



<meta property="og:title" content="Treatment cost parameters — params_costs_tx" />

<meta property="og:description" content="Information on dosage, strength, pricing, and administration costs needed
to estimate costs of treatments sequences." />
<meta name="twitter:card" content="summary" />



<!-- mathjax -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script>

<!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->


  </head>

  <body>
    <div class="container template-reference-topic">
      <header>
      <div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">iviNSCLC</a>
        <span class="version label label-danger" data-toggle="tooltip" data-placement="bottom" title="Unreleased version">1.0.0.9000</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="../reference/index.html">API</a>
</li>
<li>
  <a href="../articles/tutorial.html">Tutorial</a>
</li>
<li>
  <a href="../model-doc/model-doc.pdf">PDF documentation</a>
</li>
<li>
  <a href="../articles/source-data.html">Source data</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Web apps
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://vt-nsclc.clarityviz.com/">Basic </a>
    </li>
    <li>
      <a href="https://et-nsclc.clarityviz.com/">Advanced</a>
    </li>
  </ul>
</li>
      </ul>
      
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://github.com/InnovationValueInitiative/IVI-NSCLC">
    <span class="fa fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
      
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

      
      </header>

<div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Treatment cost parameters</h1>
    <small class="dont-index">Source: <a href='https://github.com/InnovationValueInitiative/IVI-NSCLC/blob/master/R/data.R'><code>R/data.R</code></a></small>
    <div class="hidden name"><code>params_costs_tx.Rd</code></div>
    </div>

    <div class="ref-description">
    
    <p>Information on dosage, strength, pricing, and administration costs needed
to estimate costs of treatments sequences.</p>
    
    </div>

    <pre class="usage"><span class='no'>params_costs_tx</span></pre>
        
    <h2 class="hasAnchor" id="format"><a class="anchor" href="#format"></a>Format</h2>

    <p>A list with the following elements:</p>
    
    <h2 class="hasAnchor" id="dosage"><a class="anchor" href="#dosage"></a>dosage</h2>

    
    <p>A <code>data.table</code> containing information on dosage for each
agent used for treatments that can be included in a treatment sequence. The variables
<code>strength1</code>, <code>strength2</code>, <code>quantity1</code>, <code>quantity2</code>, <code>units_per_day</code>,
and <code>duration_days</code> can be modified to change annualized costs.</p><dl class='dl-horizontal'>
<dt>agent_name</dt><dd><p>Name of the agent used in the treatment; combination therapies will have
more than one agents.</p></dd>
<dt>dosage</dt><dd><p>Amount, number. and frequency of doses over a specified time period.</p></dd>
<dt>dose</dt><dd><p>Specified amount of medication taken at one time. By default, doses
based on body surface area (BSA) and weight are based on mean BSA and weight,
respectively.</p></dd>
<dt>unit</dt><dd><p>The unit used to compute costs.</p></dd>
<dt>strength1</dt><dd><p>The amount of the drug in a single dosage form (e.g., tablet or vial).</p></dd>
<dt>strength2</dt><dd><p>If a unit consists of multiple dosage forms, then the amount of the drug
in the dosage form not included in <code>strength1</code>.</p></dd>
<dt>quantity1</dt><dd><p>Quantity of dosage form specified in <code>strength1</code> in a unit.</p></dd>
<dt>quantity2</dt><dd><p>Quantity of dosage form specified in <code>strength2</code> in a unit.</p></dd>
<dt>units_per_day</dt><dd><p>Number of units of the treatment (based on dosage) used per day.</p></dd>
<dt>duration_days</dt><dd><p>Number of days to use the treatment. If used until progression, then 
must equal <code>Inf</code>.</p></dd>
<dt>source</dt><dd><p>Source for dosage information.</p></dd>
</dl>
    
    <h2 class="hasAnchor" id="acquisition-costs"><a class="anchor" href="#acquisition-costs"></a>acquisition_costs</h2>

    
    <p>A <code>data.table</code> of acquisition costs by <code>agent</code> and <code>strength</code>.
Default costs are based on wholesale acquisition costs (WACs). The variable 
<code>acquisition_cost</code> can be modified to change annualized acquisition costs.</p><dl class='dl-horizontal'>
<dt>agent_name</dt><dd><p>Name of the agent</p></dd>
<dt>strength</dt><dd><p>The amount of the agent in a given unit of the dosage form.</p></dd>
<dt>acquisition_cost</dt><dd><p>The acquisition cost of an <code>agent</code> for a given <code>strength</code>.</p></dd>
<dt>source</dt><dd><p>Source used for <code>acquisition cost</code>.</p></dd>
</dl>
    
    <h2 class="hasAnchor" id="discounts"><a class="anchor" href="#discounts"></a>discounts</h2>

    
    <dl class='dl-horizontal'>
 <dt>agent_name</dt><dd><p>Name of the agent.</p></dd>
 <dt>discount_lower</dt><dd><p>Lower bound for discount and rebates as a 
 proportion of <code>acquisition_cost</code> in the <code>acquisition_costs</code> table.
  Assumed to follow a uniform distribution in the probabilistic sensitivity analysis.</p></dd>
 <dt>discount_upper</dt><dd><p>Upper bound for discount and rebates as a 
 proportion of <code>acquisition_cost</code> in the <code>acquisition_costs</code> table.
  Assumed to follow a uniform distribution in the probabilistic sensitivity analysis.</p></dd>
</dl>
    
    <h2 class="hasAnchor" id="administration-costs"><a class="anchor" href="#administration-costs"></a>administration_costs</h2>

    
    <p>A <code>data.table</code> of administration costs. The variable <code>costs</code>
can be modified to change annualized administration costs.</p><dl class='dl-horizontal'>
<dt>agent_name</dt><dd><p>Name of the agent.</p></dd>
<dt>administration_cost</dt><dd><p>The costs of administering an agent.</p></dd>
<dt>source</dt><dd><p>Source used for <code>administration cost</code>.</p></dd>
</dl>
    
    <h2 class="hasAnchor" id="lookup"><a class="anchor" href="#lookup"></a>lookup</h2>

    
    <p>A lookup <code>data.table</code> used to match treatments from the <code><a href='treatments.html'>treatments</a></code>
table to agents comprising a particular treatment.</p><dl class='dl-horizontal'>
<dt>tx_name</dt><dd><p>Name of treatment.</p></dd>
<dt>agent_name1</dt><dd><p>Name of first agent used for treatment.</p></dd>
<dt>agent_name2</dt><dd><p>Name of second agent used for treatment.</p></dd>
<dt>agent_name3</dt><dd><p>Name of third agent used for treatment.</p></dd>
<dt>agent_name4</dt><dd><p>Name of fourth agent used for treatment.</p></dd>
</dl>
    

    <h2 class="hasAnchor" id="examples"><a class="anchor" href="#examples"></a>Examples</h2>
    <pre class="examples"><div class='input'><span class='fu'><a href='https://www.rdocumentation.org/packages/base/topics/print'>print</a></span>(<span class='no'>params_costs_tx</span>)</div><div class='output co'>#&gt; $dosage
#&gt;        agent_name                                               dosage    dose
#&gt;  1:     erlotinib                            150 mg orally, once daily  150.00
#&gt;  2:     gefitinib                                 250 mg orally, daily  250.00
#&gt;  3:      afatinib                             40 mg orally, once daily   40.00
#&gt;  4:   dacomitinib                             45 mg orally, once daily   45.00
#&gt;  5:   osimertinib                             80 mg orally, once daily   80.00
#&gt;  6:     cisplatin                   75mg/m2, 1x/cycle, 6 21-day cycles  142.50
#&gt;  7:    pemetrexed                    500 mg, 1x/cycle, 6 21-day cycles  500.00
#&gt;  8:   bevacizumab 15mg/kg IV every 3 weeks with carboplatin/paclitaxel 1111.95
#&gt;  9:     nivolumab         240 mg every 2 weeks or 480 mg every 4 weeks  240.00
#&gt; 10: pembrolizumab                                 200 mg every 3 weeks  200.00
#&gt; 11:  atezolizumab  1200 mg as an IV infusion over 60 min every 3 weeks 1200.00
#&gt;                                     unit        strength1      strength2
#&gt;  1:                         150mg tablet     150mg tablet           &lt;NA&gt;
#&gt;  2:                         250mg tablet     250mg tablet           &lt;NA&gt;
#&gt;  3:                          40mg tablet      40mg tablet           &lt;NA&gt;
#&gt;  4:                          45mg tablet      45mg tablet           &lt;NA&gt;
#&gt;  5:                          80mg tablet      80mg tablet           &lt;NA&gt;
#&gt;  6: 1 100mg/100ml vial, 1 50mg/50ml vial 100mg/100ml vial 50mg/50ml vial
#&gt;  7:                           500mg vial       500mg vial           &lt;NA&gt;
#&gt;  8:                   3 400mg/16ml vials  400mg/16ml vial           &lt;NA&gt;
#&gt;  9:             2 100mg/10ml, 1 40mg/4ml  100mg/10ml vial  40mg/4ml vial
#&gt; 10:                     2 100mg/4ml vial   100mg/4ml vial           &lt;NA&gt;
#&gt; 11:                     1200mg/20ml vial 1200mg/20ml vial           &lt;NA&gt;
#&gt;     quantity1 quantity2 units_per_day duration_days
#&gt;  1:         1         0    1.00000000           Inf
#&gt;  2:         1         0    1.00000000           Inf
#&gt;  3:         1         0    1.00000000           Inf
#&gt;  4:         1         0    1.00000000           Inf
#&gt;  5:         1         0    1.00000000           Inf
#&gt;  6:         1         1    0.04761905           126
#&gt;  7:         1         0    0.04761905           126
#&gt;  8:         3         0    0.04761905           Inf
#&gt;  9:         2         1    0.07142857           730
#&gt; 10:         2         0    0.04761905           730
#&gt; 11:         1         0    0.04761905           730
#&gt;                                                                                                                                  source
#&gt;  1:                                                                                                                           FDA label
#&gt;  2:                                                                                                                           FDA label
#&gt;  3:                                                                                                                           FDA label
#&gt;  4:                                                                                                                           FDA label
#&gt;  5:                                                                                                                           FDA label
#&gt;  6: ICER Report Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value Based Price Benchmarks (2016)
#&gt;  7:                                                                                                                                &lt;NA&gt;
#&gt;  8:                                                                                                                           FDA label
#&gt;  9:                                                                                                                           FDA label
#&gt; 10:                                                                                                                           FDA label
#&gt; 11:                                                                                                                           FDA label
#&gt; 
#&gt; $acquisition_costs
#&gt;        agent_name         strength acquisition_cost
#&gt;  1:     erlotinib     150mg tablet         281.7133
#&gt;  2:     gefitinib     250mg tablet         257.0590
#&gt;  3:      afatinib      40mg tablet         235.0500
#&gt;  4:   dacomitinib      45mg tablet         407.3900
#&gt;  5:   osimertinib      80mg tablet         487.2157
#&gt;  6:     cisplatin   50mg/50ml vial          14.5100
#&gt;  7:     cisplatin 100mg/100ml vial          35.0000
#&gt;  8:     cisplatin 200mg/200ml vial         100.0000
#&gt;  9:    pemetrexed       100mg vial         676.5200
#&gt; 10:    pemetrexed       500mg vial        3382.6000
#&gt; 11:   carboplatin         50mg/5ml           5.9900
#&gt; 12:   carboplatin       150mg/15ml          14.2000
#&gt; 13:   carboplatin       450mg/45ml          32.9900
#&gt; 14:   carboplatin       600mg/60ml          43.9900
#&gt; 15:   gemcitabine        200mg/2mL           3.7000
#&gt; 16:   gemcitabine          1g/10mL           3.6900
#&gt; 17:   gemcitabine          2g/20mL           4.1000
#&gt; 18:     docetaxel       160mg/16ml          34.3800
#&gt; 19:     docetaxel         80mg/8ml          34.3800
#&gt; 20:     docetaxel         20mg/2ml          34.3800
#&gt; 21:    paclitaxel       300mg/50ml          55.0000
#&gt; 22:    paclitaxel     100mg/16.7ml          24.5000
#&gt; 23:    paclitaxel         30mg/5ml          10.5000
#&gt; 24:   bevacizumab   100mg/4ml vial         199.2350
#&gt; 25:   bevacizumab  400mg/16ml vial         199.2350
#&gt; 26:     nivolumab  100mg/10ml vial         262.2080
#&gt; 27:     nivolumab    40mg/4ml vial         262.2075
#&gt; 28: pembrolizumab   100mg/4ml vial        1162.4100
#&gt; 29:  atezolizumab 1200mg/20ml vial         444.0270
#&gt;        agent_name         strength acquisition_cost
#&gt;                                      source
#&gt;  1:       ProspectoRx; WAC price 12/15/2017
#&gt;  2:         ProspectoRx; WAC price 1/1/2018
#&gt;  3:         ProspectoRx; WAC price 9/1/2017
#&gt;  4:                     Public announcement
#&gt;  5:         ProspectoRx; WAC price 1/1/2018
#&gt;  6:         ProspectoRx; WAC price 3/8/2018
#&gt;  7:        ProspectoRx; WAC price 9/12/2016
#&gt;  8:       ProspectoRx; WAC price 10/17/2016
#&gt;  9:        ProspectoRx; WAC price 3/30/2018
#&gt; 10:        ProspectoRx; WAC price 3/30/2018
#&gt; 11: AnalySource 201875 (NDC: 47781-0603-20)
#&gt; 12: AnalySource 201875 (NDC: 50742-0446-15)
#&gt; 13: AnalySource 201875 (NDC: 47781-0605-94)
#&gt; 14: AnalySource 201875 (NDC: 47781-0606-94)
#&gt; 15:         ProspectoRx; WAC price 5/1/2018
#&gt; 16:         ProspectoRx; WAC price 5/1/2018
#&gt; 17:         ProspectoRx; WAC price 5/1/2018
#&gt; 18:         ProspectoRx; WAC price 9/5/2018
#&gt; 19:        ProspectoRx; WAC price 9/28/2018
#&gt; 20:        ProspectoRx; WAC price 9/28/2018
#&gt; 21:        ProspectoRx; WAC price 1/23/2018
#&gt; 22:        ProspectoRx; WAC price 1/23/2018
#&gt; 23:        ProspectoRx; WAC price 1/23/2018
#&gt; 24:         ProspectoRx; WAC price 7/1/2018
#&gt; 25:         ProspectoRx; WAC price 7/1/2018
#&gt; 26:         ProspectoRx; WAC price 4/1/2018
#&gt; 27:         ProspectoRx; WAC price 4/1/2018
#&gt; 28:        ProspectoRx; WAC price 3/22/2018
#&gt; 29:         ProspectoRx; WAC price 7/1/2018
#&gt;                                      source
#&gt; 
#&gt; $discounts
#&gt;        agent_name discount_lower discount_upper
#&gt;  1:     erlotinib            0.2            0.3
#&gt;  2:     gefitinib            0.2            0.3
#&gt;  3:      afatinib            0.2            0.3
#&gt;  4:   dacomitinib            0.2            0.3
#&gt;  5:   osimertinib            0.2            0.3
#&gt;  6:     cisplatin            0.2            0.3
#&gt;  7:    pemetrexed            0.2            0.3
#&gt;  8:   bevacizumab            0.2            0.3
#&gt;  9:     nivolumab            0.2            0.3
#&gt; 10: pembrolizumab            0.2            0.3
#&gt; 11:  atezolizumab            0.2            0.3
#&gt; 
#&gt; $administration_costs
#&gt;        agent_name administration_cost                  source
#&gt;  1:     erlotinib                0.00                     N/A
#&gt;  2:     gefitinib                0.00                     N/A
#&gt;  3:      afatinib                0.00                     N/A
#&gt;  4:   dacomitinib                0.00                     N/A
#&gt;  5:   osimertinib                0.00                     N/A
#&gt;  6:     cisplatin               91.72        CPT 96417, 96415
#&gt;  7:    pemetrexed              136.15               CPT 96413
#&gt;  8:   bevacizumab               91.72 CPT 96413, 96415, 96417
#&gt;  9:     nivolumab              136.15               CPT 96413
#&gt; 10: pembrolizumab              136.15               CPT 96413
#&gt; 11:  atezolizumab              136.15               CPT 96413
#&gt; 
#&gt; $lookup
#&gt;                                tx_name   agent_name1 agent_name2   agent_name3
#&gt;  1:                          erlotinib     erlotinib        &lt;NA&gt;          &lt;NA&gt;
#&gt;  2:                          gefitinib     gefitinib        &lt;NA&gt;          &lt;NA&gt;
#&gt;  3:                           afatinib      afatinib        &lt;NA&gt;          &lt;NA&gt;
#&gt;  4:                        dacomitinib   dacomitinib        &lt;NA&gt;          &lt;NA&gt;
#&gt;  5:                        osimertinib   osimertinib        &lt;NA&gt;          &lt;NA&gt;
#&gt;  6:                               PBDC     cisplatin  pemetrexed          &lt;NA&gt;
#&gt;  7:                        bevacizumab   bevacizumab        &lt;NA&gt;          &lt;NA&gt;
#&gt;  8:                          nivolumab     nivolumab        &lt;NA&gt;          &lt;NA&gt;
#&gt;  9:                      pembrolizumab pembrolizumab        &lt;NA&gt;          &lt;NA&gt;
#&gt; 10:                       atezolizumab  atezolizumab        &lt;NA&gt;          &lt;NA&gt;
#&gt; 11:                 PBDC + bevacizumab     cisplatin  pemetrexed   bevacizumab
#&gt; 12:                   PBDC + nivolumab     cisplatin  pemetrexed     nivolumab
#&gt; 13:               PBDC + pembrolizumab     cisplatin  pemetrexed pembrolizumab
#&gt; 14:                PBDC + atezolizumab     cisplatin  pemetrexed  atezolizumab
#&gt; 15:     PBDC + bevacizumab + nivolumab     cisplatin  pemetrexed   bevacizumab
#&gt; 16: PBDC + bevacizumab + pembrolizumab     cisplatin  pemetrexed   bevacizumab
#&gt; 17:  PBDC + bevacizumab + atezolizumab     cisplatin  pemetrexed   bevacizumab
#&gt;       agent_name4
#&gt;  1:          &lt;NA&gt;
#&gt;  2:          &lt;NA&gt;
#&gt;  3:          &lt;NA&gt;
#&gt;  4:          &lt;NA&gt;
#&gt;  5:          &lt;NA&gt;
#&gt;  6:          &lt;NA&gt;
#&gt;  7:          &lt;NA&gt;
#&gt;  8:          &lt;NA&gt;
#&gt;  9:          &lt;NA&gt;
#&gt; 10:          &lt;NA&gt;
#&gt; 11:          &lt;NA&gt;
#&gt; 12:          &lt;NA&gt;
#&gt; 13:          &lt;NA&gt;
#&gt; 14:          &lt;NA&gt;
#&gt; 15:     nivolumab
#&gt; 16: pembrolizumab
#&gt; 17:  atezolizumab
#&gt; </div></pre>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="sidebar">
    <h2>Contents</h2>
    <ul class="nav nav-pills nav-stacked">
      
      <li><a href="#format">Format</a></li>

      <li><a href="#dosage">dosage</a></li>

      <li><a href="#acquisition-costs">acquisition_costs</a></li>

      <li><a href="#discounts">discounts</a></li>

      <li><a href="#administration-costs">administration_costs</a></li>

      <li><a href="#lookup">lookup</a></li>
      
      <li><a href="#examples">Examples</a></li>
    </ul>

  </div>
</div>

      <footer>
      <div class="copyright">
  <p>Developed by Devin Incerti, Jeroen P. Jansen.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.3.0.</p>
</div>
      </footer>
   </div>

  

  </body>
</html>

